All Stories

  1. Causal diagram-derived phenotypes of urinary urgency and urgency incontinence: a matter of degree rather than distinct categories
  2. Urgency urinary incontinence, one condition, or many? Cluster analysis of physiological variables in the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) II cohort.
  3. Lessons learned from conducting a multi-center lower urinary tract physiology study: the LURN experience
  4. The National Institute of Diabetes and Digestive and Kidney Diseases Celebrates Its 75th Anniversary
  5. Validation of an Automated CT Image Analysis in the Prevention of Urinary Stones with Hydration Trial
  6. Factors associated with erectile dysfunction in men with lower urinary tract symptoms (LUTS): a Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) study
  7. Unplanned Health Care Utilization after Ureteroscopy with Ureteral Stenting: Results from the Study to Enhance Understanding of Stent-Associated Symptoms Cohort
  8. Pain After Ureteroscopy Varies by Sex and Stone Location: Findings from STENTS Study
  9. Development of Prediction Models for Severe Pain and Urinary Symptoms After Ureteroscopy With Ureteral Stent Placement: Results From the STENTS Study and Initial Validation of Pain Interference
  10. Expanded Physiological Testing of the Lower Urinary Tract in Asymptomatic Women and Those With Urgency Urinary Incontinence: Findings From the LURN‐Organ Study
  11. Widespread pain phenotypes impact treatment efficacy results in randomized clinical trials for interstitial cystitis/bladder pain syndrome: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain network study
  12. Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN): An introduction to the Urinary Urgency Phenotyping Protocol LURN II
  13. Using structured problem solving to promote fluid consumption in the prevention of urinary stones with hydration (PUSH) trial
  14. Contribution of Hypersensitivity to Postureteroscopy Ureteral Stent Pain: Findings From Study to Enhance Understanding of Stent-associated Symptoms
  15. Epidemiology of Infantile Ureteropelvic Junction Obstruction in the US
  16. Naturalistic Bladder Filling Reveals Subtypes in Overactive Bladder Syndrome That Differentially Engages Urinary Urgency-Related Brain Circuits: Results From the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  17. Reply By Authors
  18. Patients’ Experiences With the Removal of a Ureteral Stent: Insights From In-depth Interviews With Participants in the USDRN STENTS Qualitative Cohort Study
  19. Relationships Between Urinary and Nonurinary Symptoms in Treatment-Seeking Women in LURN
  20. Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study
  21. The Patient Voice: Stent Experiences After Ureteroscopy—Insights from In-Depth Interviews with Participants in the USDRN STENTS Nested Qualitative Cohort Study
  22. Risk Factors for Increased Stent-associated Symptoms Following Ureteroscopy for Urinary Stones: Results From STENTS
  23. Widespread Pain Phenotypes Impact Treatment Efficacy Results in Randomized Clinical Trials for Interstitial Cystitis/ Bladder Pain Syndrome: A MAPP Network Study
  24. Phenotyping of Urinary Urgency Patients Without Urgency Incontinence, and Their Comparison to Urgency Incontinence Patients: Findings From the LURN Study
  25. Total fluid intake, caffeine, and other bladder irritant avoidance among adults having urinary urgency with and without urgency incontinence: The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  26. Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study
  27. Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  28. Evolution of healthcare costs for lower urinary tract symptoms associated with benign prostatic hyperplasia
  29. Impact of Sleep Disturbance, Physical Function, Depression and Anxiety on Male Lower Urinary Tract Symptoms: Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  30. Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTS
  31. Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study
  32. Reply by Authors
  33. Resolution of Hydronephrosis and Pain to Predict Stone Passage for Patients With Acute Renal Colic
  34. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia
  35. Impact of COVID-19 on Prevention of Urinary Stones with Hydration (PUSH) Study: Challenges and Opportunities for Future Trials
  36. Analgesic and Opioid Use for Patients Discharged from the Emergency Department with Ureteral Stones
  37. Prevalence of Urinary Incontinence among a Nationally Representative Sample of Women, 2005–2016: Findings from the Urologic Diseases in America Project
  38. Prevention of Urinary Stones With Hydration (PUSH): Design and Rationale of a Clinical Trial
  39. Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design
  40. National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project
  41. Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms
  42. Patient demographic and psychosocial characteristics associated with 30‐day recall of self‐reported lower urinary tract symptoms
  43. Prevalence, subtypes, and correlates of nocturia in the symptoms of Lower Urinary Tract Dysfunction Research Network cohort
  44. Accuracy of Patient Reported Stone Passage for Patients With Acute Renal Colic Treated in the Emergency Department
  45. National Trends in the Surgical Management of Urinary Incontinence among Insured Women, 2004 to 2013: The Urologic Diseases in America Project
  46. A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10
  47. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project
  48. Symptom Based Clustering of Men in the LURN Observational Cohort Study
  49. Longitudinal changes in symptom‐based female and male LUTS clusters
  50. Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses
  51. Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?
  52. U.S. Adolescent and Adult Women’s Experiences Accessing and Using Toilets in Schools, Workplaces, and Public Spaces: A Multi-Site Focus Group Study to Inform Future Research in Bladder Health
  53. Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms
  54. Acyloxyacyl hydrolase modulates depressive-like behaviors through aryl hydrocarbon receptor
  55. The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations
  56. Are three‐day voiding diaries feasible and reliable? Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) cohort
  57. A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study
  58. Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project
  59. Strengthening Research in Benign Urology: Dispelling Myths that Impede Success
  60. A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index‐29 (LURN SI‐29) questionnaire
  61. The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms
  62. Optimization of DNA extraction from human urinary samples for mycobiome community profiling
  63. A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network
  64. Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms
  65. Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study
  66. Symptom Based Clustering of Women in the LURN Observational Cohort Study
  67. The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations
  68. Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence
  69. Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones
  70. Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study
  71. Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop
  72. NIH research opportunities for the prevention and treatment for chronic conditions
  73. Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence
  74. MP27-09 RELATIONSHIPS BETWEEN METABOLIC FACTORS, URINARY INCONTINENCE AND OVERACTIVE BLADDER SYMPTOMS AMONG MEN AND WOMEN IN THE LURN OBSERVATIONAL COHORT STUDY
  75. Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study
  76. Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study
  77. Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review
  78. Re: Top cited articles in urology from Turkey
  79. PNFLBA-04 RANDOMIZED CLINICAL TRIAL OF TREATMENT WITH TAMSULOSIN BEGUN IN THE EMERGENCY DEPARTMENT TO PROMOTE PASSAGE OF URINARY STONES
  80. Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department
  81. Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome
  82. Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms
  83. Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia
  84. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement
  85. Symptoms of Lower Urinary Tract Dysfunction Research Network
  86. Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health
  87. Do we need new patient reported measures to evaluate lower urinary tract dysfunction?
  88. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
  89. Quality of Acute Care for Patients With Urinary Stones in the United States
  90. Urinary Stone Disease: Progress, Status, and Needs
  91. Relationship between Chronic Nonurological Associated Somatic Syndromes and Symptom Severity in Urological Chronic Pelvic Pain Syndromes: Baseline Evaluation of the MAPP Study
  92. PD39-01 SEXUAL FUNCTION ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: MTOPS COHORT OF CROSS-SECTIONAL AND LONGITUDINAL DATA
  93. Emergency Department Revisits for Patients with Kidney Stones in California
  94. Re: Cross-Sectional and Longitudinal Associations of Sexual Function with Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  95. The International Prostate Forum introduction and history
  96. Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors
  97. Cross-Sectional and Longitudinal Associations of Sexual Function with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  98. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes
  99. The MAPP research network: design, patient characterization and operations
  100. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer
  101. Comparative Effectiveness of Shock Wave Lithotripsy and Ureteroscopy for Treating Patients With Kidney Stones
  102. Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy
  103. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer
  104. Genito-Urological Cancers in Elderly Patients
  105. Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur ...
  106. Can We Change Patient Behaviors to Improve Urological Health?
  107. Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia
  108. Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States
  109. Somatostatin receptor expression in prostate carcinoma: the urological pathologist’s role in the era of personalised medicine
  110. Active surveillance for small renal tumors: Have clinical concerns been addressed so far?
  111. Positive Surgical Margins After Nephron-Sparing Surgery
  112. Lymphocytic vasculitis of the prostate transition zone
  113. Unclassified renal cell carcinoma: a report of 56 cases
  114. Basic Research in Kidney Cancer
  115. Renal Cell Carcinoma: A Changing Paradigm With a Need for Consensus
  116. ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
  117. International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma
  118. Contemporary Management of Small Renal Masses
  119. Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and Hig...
  120. 70 INVITED New Approaches in Surgical Management of Renal Cancer
  121. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
  122. Management of advanced prostate cancer – new drugs
  123. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility
  124. 716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB
  125. Toxicities of Targeted Therapy and Their Management in Kidney Cancer
  126. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 tria...
  127. Reply to Kiril Trpkov, Asli Yilmaz’ Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patien...
  128. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Tria...
  129. Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited
  130. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use
  131. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma
  132. Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
  133. Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors
  134. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient’s Pathology and Clinical Reports
  135. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-ri...
  136. Editorial Comment on: Predicting Occult Multifocality of Renal Cell Carcinoma
  137. Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications. Eur Uro...
  138. Reply to Tomasso Cai, Lorenzo Giuseppe Luciani and Gianni Malossini’s Letter to the Editor re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comp...
  139. Ablative therapies in the treatment of small renal tumors: How far from standard of care?
  140. Reply from Authors re: Marko Babjuk. New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma. Eur Urol 2010;57:774–6
  141. The Changing Face of Renal-Cell Carcinoma
  142. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Ri...
  143. 189 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993
  144. 1474 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993
  145. Reply to José I. Lopéz's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and ...
  146. A Critical Analysis of the Actual Role of Minimally Invasive Surgery and Active Surveillance for Kidney Cancer
  147. The Motion: Cryotherapy is an Efficient Alternative for Kidney Cancer
  148. Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better
  149. What is new in kidney cancer?
  150. Kidney cancer in the elderly
  151. Genetic profiles in renal tumors
  152. Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance
  153. Secondary neoplasms of the urinary system and male genital organs
  154. Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer
  155. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?
  156. Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?
  157. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance
  158. Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
  159. Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique
  160. 2009 update on the classification of renal epithelial tumors in adults
  161. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
  162. Urologic oncology in southern Europe: Perceived problems and current plans
  163. 914 PREDICTION OF PROSTATIC INVOLVEMENT BY UROTHELIAL CARCINOMA AND OF INCIDENTAL PROSTATE CANCER IN RADICAL CYSTOPROSTATECTOMIES FOR BLADDER CANCER
  164. Editorial Comment on: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
  165. Multigene Methylation Analysis of Conventional Renal Cell Carcinoma
  166. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications
  167. Editorial Comment on: Results of Endoluminal Occlusion of the Inferior Vena Cava During Radical Nephrectomy and Thrombectomy
  168. Rare and unusual histological variants of prostatic carcinoma: clinical significance
  169. Will We Be Able to “Cure” Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?
  170. Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance
  171. Splitting and Lumping Adult Renal Epithelial Tumors Can Help the Urologists in the Prognostic Risk Stratification and in the Treatment Decision-Making
  172. PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911
  173. PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911
  174. Open Partial Nephrectomy in the Management of Small Renal Masses
  175. Chairmen's Summary
  176. Renal Cell Carcinoma: Overview
  177. A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  178. Reply to Apostolos P. Labanaris et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  179. There has to be a Way
  180. Re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  181. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion
  182. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  183. Rebuttal from Authors re: Carlo Terrone, Alessandro Volpe. The Role of Pathology for Clinical Decision-Making in Renal Cell Carcinoma is Increasing. Eur Urol 2007;51:1166–8
  184. What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?
  185. Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
  186. Re: Nephroureterectomy for Treating Upper Urinary Tract Transitional Cell Carcinoma. Time to Change the Treatment Paradigm?
  187. 1728: A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  188. The motion: Open partial nephrectomy is the standard of care for small resectable solid renal masses
  189. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  190. Editorial: Superficial Bladder Cancer
  191. Reply to Dr Özdemir’s Letter to the Editor re: Burcin Tuna, Kutsal Yorukoglu, Mehtat Unlu, M. Ugur Mungan and Ziya Kirkali, Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. Eur Urol. 2006;50:530–34
  192. Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas
  193. Puigvert: A Man with a Vision—Nephron-Sparing Surgery 30 Years Ago in Europe
  194. Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma
  195. Phase III intermittent MAB vs continuous MAB
  196. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate
  197. 2004 WHO Classification of the Renal Tumors of the Adults
  198. Expression of Cathepsin D in Bladder Carcinoma: Correlation with Pathological Features and Serum Cystatin C Levels
  199. Are We Really Making an Advance in the Treatment of Metastatic Renal Cell Carcinoma?
  200. Beyond Skeletal-Related Events
  201. Superficial Urothelial Cancer in the Prostatic Urethra
  202. Superficial Urothelial Cancer in the Prostatic Urethra
  203. Editorial: Superficial Bladder Cancer
  204. The Future of Oncological Urology in Europe: Are we Prepared?
  205. Bladder cancer: Epidemiology, staging and grading, and diagnosis
  206. Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder
  207. Echo Contrast-Enhanced Power Doppler Ultrasonography for Assessment of Angiogenesis in Renal Cell Carcinoma
  208. Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?
  209. 1,25 Dihydroxyvitamin D Receptor Expression in Superficial Transitional Cell Carcinoma of the Bladder: A Possible Prognostic Factor?
  210. Significance of COX-2 expression in human renal cell carcinoma
  211. Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report
  212. Significance of heat shock protein-27 expression in patients with renal cell carcinoma
  213. Handling and Pathology Reporting of Adrenal Gland Specimens
  214. Conservative Management of Mucosal Prostatic Urethral Involvement in Patients with Superficial Transitional Cell Carcinoma of the Bladder
  215. Handling and Pathology Reporting of Renal Tumor Specimens
  216. Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery
  217. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder
  218. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma
  219. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder
  220. Clinical Aspects of Renal Cell Carcinoma
  221. Renal cell carcinoma: new prognostic factors?
  222. Bone Mineral Density and Biochemical Markers of Bone in Patients With Idiopathic Hypercalciuria
  223. RE: Etiology of Spontaneous Perirenal Hemorrhage: A Meta-Analysis
  224. Transitional cell carcinoma of the ureter and renal pelvis
  225. Primary renal lymphoma of mucosa-associated lymphoid tissue
  226. Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer
  227. Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer
  228. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  229. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  230. Prognostic significance of nuclear morphometry in renal cell carcinoma
  231. Prognostic Significance of Estrogen Receptor Expression in Superficial Transitional Cell Carcinoma of the Urinary Bladder
  232. Management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder
  233. Phase III study of intermittent MAB versus continuous MAB international cooperative study
  234. A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell Carcinoma--A Preliminary Attempt at Surgical Quality Control
  235. Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor
  236. Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma
  237. Recent advances in kidney cancer and metastatic disease
  238. Vertebral Fracture Associated with Shockwave Lithotripsy in a Patient with Granulomatous Spondylitis
  239. INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-...
  240. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?
  241. METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: SUBCELLULAR LOCALIZATION AND PROGNOSTIC SIGNIFICANCE
  242. Quality control of radical prostatectomy
  243. Premalignant Lesions in the Kidney
  244. Expression of PS2 Protein and Its Relation with the Ki–67 Proliferative Indices and Tumor Recurrence in Superficial Bladder Carcinomas
  245. Renal Cancer
  246. Significance of Tissue Laminin P<sub>1</sub> Elastase and Fibronectin Levels in Transitional Cell Carcinoma of the Bladder
  247. Renal Cancer
  248. Precancerous Lesions in the Kidney
  249. Ganglion cells in the human prostate
  250. Prognostic Significance of Microvascular Invasion in Localized Renal Cell Carcinoma
  251. RE: RECURRENT BILATERAL AMIODARONE INDUCED EPIDIDYMITIS
  252. Prognostic significance of angiogenesis and immunoreactivity of cathepsin d and type IV collagen in high-grade stage T1 primary bladder cancer
  253. PHARMACOLOGICAL ANALYSIS OF 5-HYDROXYTRYPTAMINE EFFECTS ON HUMAN ISOLATED URETER
  254. Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma
  255. RE
  256. RE: URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER
  257. Comparison of Microvascularization in Diagnostic Needle Biopsies and Radical Prostatectomies in Prostate Carcinoma
  258. Radical Nephrectomy with and without Lymph Node Dissection: Preliminary Results of the EORTC Randomized Phase III Protocol 30881
  259. Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume
  260. Renal Effects of Carbon Dioxide Insufflation in Rabbit Pneumoretroperitoneum Model
  261. Volume-weighted mean nuclear volume in renal cell carcinoma
  262. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  263. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  264. Renal Cell Carcinoma with Gallbladder Metastasis
  265. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters
  266. Is Magnetic Resonance Imaging Necessary in the Staging of Prostate Cancer?
  267. Locally Recurrent Paratesticular Rhabdomyosarcoma Treated with Surgery and Radiotherapy
  268. Testicular Microlithiasis Associated with Teratocarcinoma and Intratubular Germ Cell Neoplasia: A Case Report
  269. Contractility Changes of the Deep Dorsal Penile Vein Due to Serotonin
  270. Ignificance of serum lam1nin P1 values in patients with transitional cell carcinoma of the bladder
  271. Effect of Extracorporeal Shockwave Lithotripsy on Plasma and Urine Endothelin Concentrations
  272. Bellini duct (collecting duct) carcinoma of the kidney
  273. Primary Kaposi's sarcoma of the glans penis
  274. Effectiveness of Extracorporeal Shockwave Lithotripsy in the Management of Stone-Bearing Horseshoe Kidneys
  275. 99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between99mTc-MIBI uptake and P-alvcoprotein expression in tumour tissue
  276. Cisplatin and Etoposide Chemotherapy in the Treatment of Adult Wilms’ Tumor
  277. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  278. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  279. Prostatic carcinoma presenting with painless parotid mass
  280. Influence of Serotonin on the Human Ureter: An in vitro Pharmacological Study
  281. Effect of Ejaculation on Prostate-Specific Antigen Levels in Normal Men
  282. Ferritin: A Tumor Marker Expressed by Renal Cell Carcinoma
  283. The effect of extracorporeal shock wave lithotripsy on pancreatic enzymes
  284. Magnetic resonance imaging in the staging of renal cell carcinoma
  285. Does Respiratory Gating Improve Extracorporeal Shockwave Lithotripsy Results?
  286. Beh�et's disease: Urogynecological manifestations in women
  287. Open stone surgery: Is it still a preferable procedure in the management of staghorn calculi?
  288. The effect of extracorporeal electromagnetic shock waves on renal proximal tubular function
  289. Primary signet-ring cell carcinoma of the bladder
  290. Are Obstructing Ureteral Stones More Difficult to Treat with Extracorporeal Electromagnetic Shock Wave Lithotripsy?*
  291. Extracorporeal Electromagnetic Shock Wave Lithotripsy of Ureteric Stones in Situ
  292. Carcinoma of the prostate and HLA antigens
  293. Carcinoma of the bladder in patients less than 40 years old
  294. Urological Aspects of Behcet's Disease
  295. Cysts of the Prostate, Seminal Vesicles and Diverticulum of the Ejaculatory Ducts
  296. Silent Testicular Metastasis from Carcinoma of the Prostate
  297. Tunica Vaginalis: an Aid in Hypospadias Surgery
  298. Androgen receptors in transitional cell carcinoma
  299. HLA Antigens and Transitional Cell Carcinoma of the Bladder
  300. Androgen Receptors - A Method to Measure Functional Behaviour in Human Prostatic Cancer
  301. Epidemiological Case-Control Study on the Etiology of Bladder Cancer in Turkey
  302. Urothelial Tumours of the Upper Urinary Tract
  303. Bladder agenesis
  304. Ureterorenoscopy: A new approach in the diagnosis and treatment of upper urinary tract disorders
  305. Amiodarone-Induced Sterile Epididymitis
  306. Blood Groups and Transitional Cell Carcinoma of the Upper Urinary Tract
  307. Spontaneous Kidney Rupture in Polyarteritis nodosa Report of Four Cases
  308. The use of oxybutynin in urological practice
  309. Ureteric perforation after ureteroscopy
  310. Androgen receptors in TCC
  311. Unusual Metastases of Renal Cell Carcinoma
  312. The role of delay in stage III testicular tumours
  313. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate
  314. The Role of Delay in Stage-Ill Testicular Tumors
  315. Haemoglobin F Levels in Patients with Testicular Tumours
  316. Experience with Treatment of Nonseminomatous Germ Cell Tumors of Testis in Turkey
  317. Advanced Tumors: Tumor Thrombus